Fig. 1.

Clinical outcome scale scores pre- and post-intravenous golimumab treatment. Mean patient clinical outcome scores for the a CDAI and b PhGA are presented for the respective samples (CDAI, n = 22 and PhGA, n = 25). Pre-period scores were collected within the 90 days before intravenous golimumab treatment, and post-period scores were the most recent score on record while the patient was receiving intravenous golimumab for rheumatoid arthritis. For each clinical score, centered bars represent the mean, and error bars represent the standard deviation. CDAI Clinical Disease Assessment, IV intravenous, PhGA Physician Global Assessment